Enliven Therapeutics, Inc. 8-K

What Happened
Enliven Therapeutics, Inc. announced on May 7, 2026 that it issued a press release reporting its financial results for the quarter ended March 31, 2026. The full text of that press release is attached to the 8‑K as Exhibit 99.1 and is incorporated by reference into the filing.

Key Details

• Date of announcement: May 7, 2026.
• Period covered: quarter ended March 31, 2026.
• The press release containing the full financial results is attached as Exhibit 99.1 to the Form 8‑K.
• Per Item 9.01, the information and Exhibit 99.1 are furnished (not “filed”) and are not subject to Section 18 liability or automatically incorporated by reference into other SEC filings unless expressly stated.

Why It Matters
This 8‑K signals that Enliven has released its latest quarterly earnings and related financial details — information investors use to evaluate recent performance and near‑term prospects. Because the press release is furnished rather than filed, legal liability and incorporation rules differ; investors should read Exhibit 99.1 for the actual revenue, profit/loss, cash position, and any management commentary or guidance, and monitor subsequent SEC filings (e.g., Form 10‑Q) for audited or more detailed financial statements. Keywords: earnings, quarterly results, financial results.